AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19
Copyright © 2021 by the American Society of Nephrology..
BACKGROUND: AKI is a common sequela of coronavirus disease 2019 (COVID-19). However, few studies have focused on AKI treated with RRT (AKI-RRT).
METHODS: We conducted a multicenter cohort study of 3099 critically ill adults with COVID-19 admitted to intensive care units (ICUs) at 67 hospitals across the United States. We used multivariable logistic regression to identify patient-and hospital-level risk factors for AKI-RRT and to examine risk factors for 28-day mortality among such patients.
RESULTS: A total of 637 of 3099 patients (20.6%) developed AKI-RRT within 14 days of ICU admission, 350 of whom (54.9%) died within 28 days of ICU admission. Patient-level risk factors for AKI-RRT included CKD, men, non-White race, hypertension, diabetes mellitus, higher body mass index, higher d-dimer, and greater severity of hypoxemia on ICU admission. Predictors of 28-day mortality in patients with AKI-RRT were older age, severe oliguria, and admission to a hospital with fewer ICU beds or one with greater regional density of COVID-19. At the end of a median follow-up of 17 days (range, 1-123 days), 403 of the 637 patients (63.3%) with AKI-RRT had died, 216 (33.9%) were discharged, and 18 (2.8%) remained hospitalized. Of the 216 patients discharged, 73 (33.8%) remained RRT dependent at discharge, and 39 (18.1%) remained RRT dependent 60 days after ICU admission.
CONCLUSIONS: AKI-RRT is common among critically ill patients with COVID-19 and is associated with a hospital mortality rate of >60%. Among those who survive to discharge, one in three still depends on RRT at discharge, and one in six remains RRT dependent 60 days after ICU admission.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Journal of the American Society of Nephrology : JASN - 32(2021), 1 vom: 18. Jan., Seite 161-176 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gupta, Shruti [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute kidney injury |
|---|
| Anmerkungen: |
Date Completed 17.03.2021 Date Revised 30.03.2024 published: Print-Electronic CommentIn: J Am Soc Nephrol. 2020 Oct 28;:. - PMID 33115918 Citation Status MEDLINE |
|---|
| doi: |
10.1681/ASN.2020060897 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316368385 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316368385 | ||
| 003 | DE-627 | ||
| 005 | 20240330233111.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1681/ASN.2020060897 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM316368385 | ||
| 035 | |a (NLM)33067383 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gupta, Shruti |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.03.2021 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Am Soc Nephrol. 2020 Oct 28;:. - PMID 33115918 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 by the American Society of Nephrology. | ||
| 520 | |a BACKGROUND: AKI is a common sequela of coronavirus disease 2019 (COVID-19). However, few studies have focused on AKI treated with RRT (AKI-RRT) | ||
| 520 | |a METHODS: We conducted a multicenter cohort study of 3099 critically ill adults with COVID-19 admitted to intensive care units (ICUs) at 67 hospitals across the United States. We used multivariable logistic regression to identify patient-and hospital-level risk factors for AKI-RRT and to examine risk factors for 28-day mortality among such patients | ||
| 520 | |a RESULTS: A total of 637 of 3099 patients (20.6%) developed AKI-RRT within 14 days of ICU admission, 350 of whom (54.9%) died within 28 days of ICU admission. Patient-level risk factors for AKI-RRT included CKD, men, non-White race, hypertension, diabetes mellitus, higher body mass index, higher d-dimer, and greater severity of hypoxemia on ICU admission. Predictors of 28-day mortality in patients with AKI-RRT were older age, severe oliguria, and admission to a hospital with fewer ICU beds or one with greater regional density of COVID-19. At the end of a median follow-up of 17 days (range, 1-123 days), 403 of the 637 patients (63.3%) with AKI-RRT had died, 216 (33.9%) were discharged, and 18 (2.8%) remained hospitalized. Of the 216 patients discharged, 73 (33.8%) remained RRT dependent at discharge, and 39 (18.1%) remained RRT dependent 60 days after ICU admission | ||
| 520 | |a CONCLUSIONS: AKI-RRT is common among critically ill patients with COVID-19 and is associated with a hospital mortality rate of >60%. Among those who survive to discharge, one in three still depends on RRT at discharge, and one in six remains RRT dependent 60 days after ICU admission | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a acute kidney injury | |
| 650 | 4 | |a acute renal failure | |
| 650 | 4 | |a clinical epidemiology | |
| 650 | 4 | |a dialysis | |
| 650 | 4 | |a renal replacement therapy | |
| 650 | 4 | |a risk factors | |
| 700 | 1 | |a Coca, Steven G |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Lili |e verfasserin |4 aut | |
| 700 | 1 | |a Melamed, Michal L |e verfasserin |4 aut | |
| 700 | 1 | |a Brenner, Samantha K |e verfasserin |4 aut | |
| 700 | 1 | |a Hayek, Salim S |e verfasserin |4 aut | |
| 700 | 1 | |a Sutherland, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Puri, Sonika |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastava, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Leonberg-Yoo, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Shehata, Alexandre M |e verfasserin |4 aut | |
| 700 | 1 | |a Flythe, Jennifer E |e verfasserin |4 aut | |
| 700 | 1 | |a Rashidi, Arash |e verfasserin |4 aut | |
| 700 | 1 | |a Schenck, Edward J |e verfasserin |4 aut | |
| 700 | 1 | |a Goyal, Nitender |e verfasserin |4 aut | |
| 700 | 1 | |a Hedayati, S Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Dy, Rajany |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, Anip |e verfasserin |4 aut | |
| 700 | 1 | |a Athavale, Ambarish |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, H Bryant |e verfasserin |4 aut | |
| 700 | 1 | |a Vijayan, Anitha |e verfasserin |4 aut | |
| 700 | 1 | |a Charytan, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Schulze, Carl E |e verfasserin |4 aut | |
| 700 | 1 | |a Joo, Min J |e verfasserin |4 aut | |
| 700 | 1 | |a Friedman, Allon N |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Sosa, Marie Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Judd, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Velez, Juan Carlos Q |e verfasserin |4 aut | |
| 700 | 1 | |a Mallappallil, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Redfern, Roberta E |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, Amar D |e verfasserin |4 aut | |
| 700 | 1 | |a Neyra, Javier A |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Kathleen D |e verfasserin |4 aut | |
| 700 | 1 | |a Renaghan, Amanda D |e verfasserin |4 aut | |
| 700 | 1 | |a Christov, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Molnar, Miklos Z |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Shreyak |e verfasserin |4 aut | |
| 700 | 1 | |a Kamal, Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Boateng, Jeffery Owusu |e verfasserin |4 aut | |
| 700 | 1 | |a Short, Samuel A P |e verfasserin |4 aut | |
| 700 | 1 | |a Admon, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Sise, Meghan E |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Chirag R |e verfasserin |4 aut | |
| 700 | 1 | |a Leaf, David E |e verfasserin |4 aut | |
| 700 | 0 | |a and the STOP-COVID Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Walther, Carl P |e investigator |4 oth | |
| 700 | 1 | |a Anumudu, Samaya J |e investigator |4 oth | |
| 700 | 1 | |a Arunthamakun, Justin |e investigator |4 oth | |
| 700 | 1 | |a Kopecky, Kathleen F |e investigator |4 oth | |
| 700 | 1 | |a Milligan, Gregory P |e investigator |4 oth | |
| 700 | 1 | |a McCullough, Peter A |e investigator |4 oth | |
| 700 | 1 | |a Nguyen, Thuy-Duyen |e investigator |4 oth | |
| 700 | 1 | |a Shaefi, Shahzad |e investigator |4 oth | |
| 700 | 1 | |a Krajewski, Megan L |e investigator |4 oth | |
| 700 | 1 | |a Shankar, Sidharth |e investigator |4 oth | |
| 700 | 1 | |a Pannu, Ameeka |e investigator |4 oth | |
| 700 | 1 | |a Valencia, Juan D |e investigator |4 oth | |
| 700 | 1 | |a Waikar, Sushrut S |e investigator |4 oth | |
| 700 | 1 | |a Kibbelaar, Zoe A |e investigator |4 oth | |
| 700 | 1 | |a Hart, Peter |e investigator |4 oth | |
| 700 | 1 | |a Upadhyay, Shristi |e investigator |4 oth | |
| 700 | 1 | |a Vohra, Ishaan |e investigator |4 oth | |
| 700 | 1 | |a Green, Adam |e investigator |4 oth | |
| 700 | 1 | |a Rachoin, Jean-Sebastien |e investigator |4 oth | |
| 700 | 1 | |a Schorr, Christa A |e investigator |4 oth | |
| 700 | 1 | |a Shea, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Edmonston, Daniel L |e investigator |4 oth | |
| 700 | 1 | |a Mosher, Christopher L |e investigator |4 oth | |
| 700 | 1 | |a Cohen, Zaza |e investigator |4 oth | |
| 700 | 1 | |a Allusson, Valerie |e investigator |4 oth | |
| 700 | 1 | |a Bambrick-Santoyo, Gabriela |e investigator |4 oth | |
| 700 | 1 | |a Bhatti, Noor Ul Aain |e investigator |4 oth | |
| 700 | 1 | |a Mehta, Bijal |e investigator |4 oth | |
| 700 | 1 | |a Williams, Aquino |e investigator |4 oth | |
| 700 | 1 | |a Walters, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Go, Ronaldo C |e investigator |4 oth | |
| 700 | 1 | |a Rose, Keith M |e investigator |4 oth | |
| 700 | 1 | |a Lisk, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Zhou, Amy M |e investigator |4 oth | |
| 700 | 1 | |a Kim, Ethan C |e investigator |4 oth | |
| 700 | 1 | |a Mathews, Kusum S |e investigator |4 oth | |
| 700 | 1 | |a Altman, Deena R |e investigator |4 oth | |
| 700 | 1 | |a Saha, Aparna |e investigator |4 oth | |
| 700 | 1 | |a Soh, Howard |e investigator |4 oth | |
| 700 | 1 | |a Wen, Huei Hsun |e investigator |4 oth | |
| 700 | 1 | |a Bose, Sonali |e investigator |4 oth | |
| 700 | 1 | |a Leven, Emily A |e investigator |4 oth | |
| 700 | 1 | |a Wang, Jing G |e investigator |4 oth | |
| 700 | 1 | |a Mosoyan, Gohar |e investigator |4 oth | |
| 700 | 1 | |a Nadkarni, Girish N |e investigator |4 oth | |
| 700 | 1 | |a Pattharanitima, Pattharawin |e investigator |4 oth | |
| 700 | 1 | |a Gallagher, Emily J |e investigator |4 oth | |
| 700 | 1 | |a Guirguis, John |e investigator |4 oth | |
| 700 | 1 | |a Kapoor, Rajat |e investigator |4 oth | |
| 700 | 1 | |a Meshberger, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Kelly, Katherine J |e investigator |4 oth | |
| 700 | 1 | |a Garibaldi, Brian T |e investigator |4 oth | |
| 700 | 1 | |a Corona-Villalobos, Celia P |e investigator |4 oth | |
| 700 | 1 | |a Wen, Yumeng |e investigator |4 oth | |
| 700 | 1 | |a Menez, Steven |e investigator |4 oth | |
| 700 | 1 | |a Malik, Rubab F |e investigator |4 oth | |
| 700 | 1 | |a Cervantes, Carmen Elena |e investigator |4 oth | |
| 700 | 1 | |a Gautam, Samir C |e investigator |4 oth | |
| 700 | 1 | |a Ouyang, Jie |e investigator |4 oth | |
| 700 | 1 | |a John, Sabu |e investigator |4 oth | |
| 700 | 1 | |a Yap, Ernie |e investigator |4 oth | |
| 700 | 1 | |a Melaku, Yohannes |e investigator |4 oth | |
| 700 | 1 | |a Mohamed, Ibrahim |e investigator |4 oth | |
| 700 | 1 | |a Bajracharya, Siddhartha |e investigator |4 oth | |
| 700 | 1 | |a Puri, Isha |e investigator |4 oth | |
| 700 | 1 | |a Thaxton, Mariah |e investigator |4 oth | |
| 700 | 1 | |a Bhattacharya, Jyotsna |e investigator |4 oth | |
| 700 | 1 | |a Wagner, John |e investigator |4 oth | |
| 700 | 1 | |a Boudourakis, Leon |e investigator |4 oth | |
| 700 | 1 | |a Ahoubim, Afshin |e investigator |4 oth | |
| 700 | 1 | |a Thomas, Leslie F |e investigator |4 oth | |
| 700 | 1 | |a Sirganagari, Dheeraj Reddy |e investigator |4 oth | |
| 700 | 1 | |a Guru, Pramod K |e investigator |4 oth | |
| 700 | 1 | |a Zhou, Yan |e investigator |4 oth | |
| 700 | 1 | |a Bergl, Paul A |e investigator |4 oth | |
| 700 | 1 | |a Rodriguez, Jesus |e investigator |4 oth | |
| 700 | 1 | |a Shah, Jatan A |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Mrigank S |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Princy N |e investigator |4 oth | |
| 700 | 1 | |a Lazarous, Deepa G |e investigator |4 oth | |
| 700 | 1 | |a Kassaye, Seble G |e investigator |4 oth | |
| 700 | 1 | |a Johns, Tanya S |e investigator |4 oth | |
| 700 | 1 | |a Mocerino, Ryan |e investigator |4 oth | |
| 700 | 1 | |a Prudhvi, Kalyan |e investigator |4 oth | |
| 700 | 1 | |a Zhu, Denzel |e investigator |4 oth | |
| 700 | 1 | |a Levy, Rebecca V |e investigator |4 oth | |
| 700 | 1 | |a Azzi, Yorg |e investigator |4 oth | |
| 700 | 1 | |a Fisher, Molly |e investigator |4 oth | |
| 700 | 1 | |a Yunes, Milagros |e investigator |4 oth | |
| 700 | 1 | |a Sedaliu, Kaltrina |e investigator |4 oth | |
| 700 | 1 | |a Golestaneh, Ladan |e investigator |4 oth | |
| 700 | 1 | |a Brogan, Maureen |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Neelja |e investigator |4 oth | |
| 700 | 1 | |a Chang, Michael |e investigator |4 oth | |
| 700 | 1 | |a Thakkar, Jyotsana |e investigator |4 oth | |
| 700 | 1 | |a Raichoudhury, Ritesh |e investigator |4 oth | |
| 700 | 1 | |a Athreya, Akshay |e investigator |4 oth | |
| 700 | 1 | |a Farag, Mohamed |e investigator |4 oth | |
| 700 | 1 | |a Cho, Soo Jung |e investigator |4 oth | |
| 700 | 1 | |a Plataki, Maria |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Society of Nephrology : JASN |d 1990 |g 32(2021), 1 vom: 18. Jan., Seite 161-176 |w (DE-627)NLM012606502 |x 1533-3450 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:1 |g day:18 |g month:01 |g pages:161-176 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1681/ASN.2020060897 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2021 |e 1 |b 18 |c 01 |h 161-176 | ||